Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Baxter
Colorcon
McKesson
Moodys

Last Updated: December 16, 2019

DrugPatentWatch Database Preview

Litigation Details for Cadence Pharmaceuticals Inc. v. Exela Pharma Sciences LLC (D. Del. 2011)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Cadence Pharmaceuticals Inc. v. Exela Pharma Sciences LLC (D. Del. 2011)

Docket   Start Trial Date Filed 2011-08-18
Court District Court, D. Delaware Date Terminated 2013-11-22
Cause 35:271 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand None Referred To
Parties CADENCE PHARMACEUTICALS INC.; EXELA HOLDINGS INC.; EXELA PHARMA SCIENCES LLC; EXELA PHARMSCI INC.; PADDOCK LABORATORIES INC.; PADDOCK LABORATORIES LLC; PERRIGO COMPANY; SCR PHARMATOP
Patents 6,028,222; 6,992,218
Attorneys Adam Wyatt Poff; Jack B. Blumenfeld; Richard L. Horwitz; Robert J. Katzenstein; Thomas C. Grimm
Link to Docket External link to docket
Small Molecule Drugs cited in Cadence Pharmaceuticals Inc. v. Exela Pharma Sciences LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Cadence Pharmaceuticals Inc. v. Exela Pharma Sciences LLC (D. Del. 2011)

Date Filed Document No. Description Snippet Link To Document
2012-08-22 188 terms found in U.S. Patent Nos. 6,028,222 (the '"222 patent") and 6,992,218 (the …the "'218 patent") ~ I (collectively, the "patents-in-suit"). l I. …alleging infringement of ~ i the patents-in-suit. (D.I. 1) The patents-in-suit relate to formulations and…acetaminophen. (See '222 patent col.l8 11.50-55) The '218 patent relates to an "extreme…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which External link to document
2012-10-01 225 Plaintiffs allege infringement of U.S. Patent Nos. 6,028,222 and 6,99 ,218 as a result of an Abbreviated… 6. "Patent misuse is an affirmative defen e to an accusation of patent infringement, …Filing of al suit for patent infringement can constitute I ~ patent misuse if the suit was…#39;a claim of a patent is invalid,"' but "an issued patent is presu ed valid,"… "Plaintiffs") filed this action for patent infringement gainst Paddock Laboratories, Inc.; External link to document
2012-10-04 231 infringement of U.S. Patent Nos. 6,028,222 (the ’222 patent) and 6,992,218 (the ’21 8 patent) under 35 U.S.C…rights in the patents-in-suit. Plaintiff SCR Pharmatop, the patent owner, licensed the patents to BMS. BMS…sublicensed the patents to plaintiff Cadence but BMS retained substantial rights in the patents _ Th@r€f@r@… “ALL SUBSTANTIAL RIGHTS” IN THE PATENTS Standing to bring a patent suit is a question of subject matter… of the patent, such that the exclusive licensee holds “all substantial rights” in the patent. Alfr" External link to document
2012-10-24 249 8. The term “the Patents~in-Suit” means U.S. Patent No. 6,028,222 and U.S. Patent No. 6,992,218, collectively…Paddook”);_ WHEREAS, Plaintiffs suedPaddocl< for patent infringement based on Paddock’s filing of ANDA…concerning the use of any information set forth in the Patents- in-Suit during the development of the Paddock … 22 November 2013 1:11-cv-00733-LPS Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Dow
AstraZeneca
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.